Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNT1 | O60563 | 11/20 | 0.54 |
| ▸ | CDK9 | P50750 | 11/20 | 0.54 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.45 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.45 |
| ▸ | TRPV1 | Q8NER1 | 5/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.43 |
| ▸ | LIMK2 | P53671 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14500374 | 0.94 | CCNT1 (0.48) | CCNT1CDK9ROCK2ROCK1TRPV1 | |
| SCHEMBL14500373 | 0.94 | CCNT1 (0.47) | CCNT1CDK9ROCK2ROCK1TRPV1 | |
| SCHEMBL14500362 | 0.93 | CCNT1 (0.54) | CCNT1CDK9 | |
| SCHEMBL14500371 | 0.92 | CDK9 (0.53) | CCNT1CDK9ROCK2ROCK1LIMK1 | |
| SCHEMBL14500376 | 0.92 | CDK9 (0.46) | CCNT1CDK9ROCK2ROCK1TRPV1 | |
| SCHEMBL14500338 | 0.91 | CCNT1 (0.51) | CCNT1CDK9 | |
| SCHEMBL14500368 | 0.91 | CCNT1 (0.52) | CCNT1CDK9 | |
| SCHEMBL14500357 | 0.91 | CDK9 (0.44) | CCNT1CDK9ROCK2ROCK1 | |
| SCHEMBL14500340 | 0.90 | CCNT1 (0.53) | CCNT1CDK9NPC1RAB9ALIMK1 | |
| SCHEMBL14500311 | 0.90 | CDK9 (0.47) | CCNT1CDK9ROCK2ROCK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2007067537-A1 | PYRROLOPYRIDINE KINASE INHIBITING COMPOUNDS | OSI PHARMACEUTICALS, INC. (US) | 2007-06-14 | — | — | WO | disclosed |
| US-20070129364-A1 | Pyrrolopyridine kinase inhibiting compounds | OSI PHARMACEUTICALS, INC. | 2007-06-07 | — | — | US | disclosed |
| US-20070129364-A1 | Pyrrolopyridine kinase inhibiting compounds | OSI PHARMACEUTICALS, INC. | 2007-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070129364-A1 | Pyrrolopyridine kinase inhibiting compounds | BMX, ERBB2, FRK | CCNT1 1682/4885CDK9 392/4885ROCK2 49/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.